Pemetrexed/Carboplatin

Phase 3Small molecule

Pemetrexed/Carboplatin is one of 82 small molecule programs targeting Non-small Cell Lung Cancer (NSCLC). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung Cancer (NSCLC)Active, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

MalignanciesRecruiting

Non-Small Cell Lung Cancer (NSCLC)Phase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

MalignanciesPhase 1

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

1 2

Pemetrexed/Carboplatin

AstraZeneca

Phase 3

6 3

Anktiva

SSWOG Cancer Research Network

Phase 3

1 4

Carboplatin/paclitaxel

AstraZeneca

Phase 3

3 5

Remeron

OOrganon and Co

Preclinical

1 6

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Non-Small Cell Lung Cancer (NSCLC)

NCT03775486

Q3 2027

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT04035486

Q4 2027

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT05668988

Phase 1Recruiting

Malignancies

NCT07004244

Q2 2030

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT05061550

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer6 trials

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Completed· Pfizer logo

Pfizer·Phase 3·NCT01639001·207 enrolled

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

Unknown status·HHenan Cancer Hospital·Phase 2·NCT02737774·60 enrolled

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Active, not recruiting·DDizal Pharmaceuticals·Phase 3·NCT05668988·324 enrolled

Show 3 more trials

A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemo, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2).

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04035486·587 enrolled

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT05061550·630 enrolled

The Efficacy and Safety of Osimertinib Plus Carboplatin and Pemetrexed Versus Osimertinib Monotherapy in Metastatic EGFRm NSCLC Patients With EGFRm Persistence in ctDNA at 3 Weeks After 1L Osimertinib: A Multicenter, Randomized Controlled Study

Completed·BBeijing Cancer Prevention & Treatment Society·Phase 2·NCT04769388·80 enrolled

Advanced or Metastatic NSCLC1 trial

A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC

Withdrawn·NNextCure, Inc.·Phase 1/2·NCT04430933

Malignancies1 trial

Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies

Recruiting·SSichuan University·Phase 1·NCT07004244·20 enrolled

Small Cell Lung Cancer1 trial

Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients

Terminated·—·Phase 2·NCT00754364·108 enrolled

Non-small Cell Lung Cancer (NSCLC)1 trial

A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab Plus Olaparib Combination Therapy Compared With Durvalumab Monotherapy as Maintenance Therapy in Patients Whose Disease Has Not Progressed Following Standard of Care Platinum-Based Chemotherapy With Durvalumab in First Line Stage IV Non Small Cell Lung Cancer (ORION)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT03775486·401 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Pemetrexed/Carboplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pemetrexed/Carboplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pemetrexed/Carboplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Pemetrexed/Carboplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2027

Q4 2027

Q2 2030

Trials by Indication[1]

Non-Small Cell Lung Cancer6 trials

Advanced or Metastatic NSCLC1 trial

Malignancies1 trial

Small Cell Lung Cancer1 trial

Non-small Cell Lung Cancer (NSCLC)1 trial

References

Drug Info

Quick Facts

Related News